Seegene Inc, a South Korea-based developer of molecular diagnostics (MDx) solutions, announced on Tuesday the launch of STAgora, a next-generation platform for infectious disease analytics.
Designed as a real-time infectious disease intelligence system, the company says that the platform combines diagnostic data with advanced statistical modelling and aims to redefine how the world detects, tracks and responds to outbreaks.
STAgora provides real-time global visualisation of infectious disease trends at the municipal, national and continental levels, based on actual diagnostic test results. It also delivers healthcare professionals immediate, structured diagnostic reports and statistical analyses in clear, actionable formats. These are supported by customisable dashboards and real-time alert functions.
In addition to tracking individual cases, STAgora enables users to monitor outbreaks across selected regions, both local and international. This capability is designed to provide real-time visibility into disease spread, enhancing situational awareness and supporting timely, data-driven public health responses. By equipping national and global health authorities with real-time epidemiological insight, the platform is expected to strengthen decision-making and support the development of effective response strategies to mitigate large-scale infectious disease outbreaks.
Seegene says that it will officially debut STAgora at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting, taking place from 27 to 31 July in Chicago, USA. The event will highlight key capabilities of the platform, including its integration with CURECA, Seegene's fully automated, unmanned PCR system. ADLM 2025 will also serve as a launchpad for Seegene to explore global collaboration and partnerships with healthcare leaders and clients.
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Roche expands cyclospora testing portfolio to support US public health response
Decoy Therapeutics expands antiviral platform into Ebola and filovirus research
ABL Diagnostics selected to acquire TEXCELL operations
Aptamer Group launches Optimer-based Ebola diagnostic programme
Physiomics secures new contracts worth over GBP200,000
EDX Medical to provide molecular profiling services to Astron Health
Sanofi appoints new global head of Research & Development Pharma
Lakewood-Amedex expands intellectual property portfolio with Australian Bisphosphocin patent
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB
Gilead Sciences mobilises remdesivir donation to support Ebola response in Uganda